Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE: DNA · IEX Real-Time Price · USD
3.66
+0.26 (7.50%)
Aug 12, 2022 11:45 AM EDT - Market open
7.50%
Market Cap 6.51B
Revenue (ttm) 438.15M
Net Income (ttm) -2.35B
Shares Out 1.78B
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,435,607
Open 3.53
Previous Close 3.40
Day's Range 3.38 - 3.73
52-Week Range 2.09 - 15.86
Beta n/a
Analysts Buy
Price Target 7.56 (+106.8%)
Earnings Date Aug 15, 2022

About DNA

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in... [Read more...]

Industry Biotechnology
Founded 2008
Employees 641
Stock Exchange NYSE
Ticker Symbol DNA
Full Company Profile

Financial Performance

In 2021, DNA's revenue was $313.84 million, an increase of 309.40% compared to the previous year's $76.66 million. Losses were -$1.83 billion, 1,345.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for DNA stock is "Buy." The 12-month stock price forecast is 7.56, which is an increase of 106.84% from the latest price.

Price Target
$7.56
(106.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic CAMBRIDGE, Mass. and BOSTON , Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a ...

Other symbols: SYBX

Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities...

Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy BOSTON and KIGALI, Rwanda , Aug. 11, 2022 /...

10 Stocks That Could Rise 10x (Safely)

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 9, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

Ginkgo Bioworks Announces Date of Second Quarter 2022 Results Presentation

Presentation and Q&A session scheduled for post-market on Monday, August 15, 2022 BOSTON , Aug. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming,...

Should You Really Be Buying Beaten-Down Growth Stocks Right Now?

Now's a great time to invest in companies with the potential to grow significantly in the long term.

Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future

Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.

Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors

BOSTON , Aug. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Dire...

Clinical Enterprise, Inc. and Ginkgo Bioworks to Continue Support of Federal COVID-19 Testing Program Through 2022

FRAMINGHAM, Mass. & BOSTON--(BUSINESS WIRE)--Clinical Enterprise, Inc., a member of the Eurofins Clinical Diagnostic group of companies, today announced that it is extending its partnership with Ginkgo ...

SHAREHOLDER ALERT: Weiss Law Investigates Infrastructure and Zymergen Inc.

NEW YORK , July 25, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zymergen Inc. ("Zymergen" or the "Company...

Other symbols: ZY

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Zymergen Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - July 25, 2022) - Rigrodsky Law, P.A. is investigating Zymergen Inc. ("Zymergen") (NASDAQ GS: ZY) regarding possible breaches of fiduciary duties and other violati...

ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zymergen Inc. (Nas...

Other symbols: ZY

Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?

DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site. The post Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?

Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million

The deal values Zymergen at a fraction of its $3 billion valuation at Zymergen's IPO last April.

Other symbols: ZY

Ginkgo to Acquire Zymergen

Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platform Expect integration of Zymergen's complementary automation, software, and data science t...

Other symbols: ZY

Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities

Ginkgo to acquire Bayer's 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs BOSTON , July 25,...

Ginkgo Bioworks Announces Latest Collaboration for Beauty and Personal Care Industry with Sumitomo Chemical

BOSTON , July 18, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the launch of a new cell programming project as part of a broade...

Ginkgo Bioworks Publishes Inaugural Sustainability Report

The report, "Caring at Ginkgo," outlines the company's approach to sustainability, internal governance structures, and how its cell engineering platform is deployed BOSTON , July 14, 2022 /PRNewswire/ -...

Cathie Wood Just Doubled Down on Ginkgo Bioworks (DNA) Stock

While Ginkgo Bioworks may be a relatively unknown name to many investors, DNA stock is quite well-known to Cathie Wood and her Ark funds. The post Cathie Wood Just Doubled Down on Ginkgo Bioworks (DNA) ...

Billionaire Andreas Halvorsen Just Bought DNA Stock. Here's Why.

DNA stock is surging higher today following large purchases from Viking Global's Andreas Halvorsen and Ark Invest's Cathie Wood. The post Billionaire Andreas Halvorsen Just Bought DNA Stock.

Beware These 7 Penny Stock Bubbles Getting Ready to Burst

The following penny stocks have built up a large bubble that is yet to burst. They are likely to burst soon due to the market decline.

Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Stock

Cathie Wood's Ark Invest has purchased more than 3.5 million shares of DNA stock since June 29, its first purchases in over a month. The post Cathie Wood Is Making a Big Bet on Gingko Bioworks (DNA) Sto...

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity mi...

Other symbols: CRON

Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

TORONTO and BOSTON , June 21, 2022 /PRNewswire/ -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) ("Ginkgo"), the lead...

Other symbols: CRON

3 Stocks Down 50% or More That You Can Buy Right Now

Huge rebounds could be in store for these beaten-down stocks.

Other symbols: NVAXNVCR

Ginkgo Bioworks Announces Participation in Goldman Sachs 43rd Annual Global Healthcare Conference

BOSTON , June 10, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in Goldman Sachs' 43...